Karolinska Development has a focused portfolio comprising pharmaceutical and medtech companies with significant potential for value generation. The portfolio companies develop highly differentiated and commercially attractive products that have the potential to deliver compelling clinical and health economic benefits, as well as attractive returns on investment.